Peter L. Hoang has bought MRKR on 2 days since Aug 2019

Hoang Peter L. is an individual corporate insider and biotechnology executive who served as President and Chief Executive Officer of Marker Therapeutics, Inc. (Nasdaq: MRKR) from 2017 to 2023.( At Marker, he led a clinical-stage immuno-oncology company focused on next-generation, multi-antigen targeted T cell therapies for cancer indications including AML, lymphoma, multiple myeloma, and pancreatic cancer.(

Before joining Marker, Hoang built a career across biotechnology, venture creation, and healthcare finance. He previously served as President & CEO of TapImmune and as Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, where he led new venture formation and development efforts.( Earlier in his career, he was a senior investment banker, including as Managing Director and head of healthcare M&A advisory at CIT Group, and also worked in M&A roles at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank.( He earned an MBA with high honors from UCLA’s Anderson School of Management and a BA from Yale University.(

Written by Perplexity from public sources.